AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02834780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6527
Description: H3B-6527 by mouth once or twice daily at specified doses.
Study NCT03969862 — intervention group
Intervention type: DEVICE
Intervention: NOVEOS® system
Description: The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark.
Study NCT03449030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-164
Description: TAK-164 intravenous infusion.
Study NCT03449030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-TAK-164
Description: 89Zr-TAK-164 intravenous infusion
Study NCT00062127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00062127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00062127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02270450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo abdominal surgery
Study NCT02270450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrointestinal complications management/prevention
Description: Undergo non-surgical management
Study NCT02270450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02912975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile treatment
Description: In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
Study NCT02363738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
Study NCT04019782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen-PVP
Description: Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)
Study NCT04019782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)
Study NCT03219814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Body Project
Description: The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
Study NCT03219814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediapsychoeducation
Description: Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
Study NCT01056237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-target therapy
Description: Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
Study NCT01056237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 1.0-2.0mg/kg/d
Study NCT01288196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: A single 30-minute IV infusion of placebo
Study NCT01288196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 1 mg/kg IV
Description: A single 30-minute IV infusion of CNTO 6785 1 mg/kg
Study NCT01288196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 3 mg/kg IV
Description: A single 30-minute IV infusion of CNTO 6785 3 mg/kg
Study NCT01288196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 10 mg/kg IV
Description: A single 30-minute IV infusion of CNTO 6785 10 mg/kg
Study NCT00739024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: 8 mg tablet, oral, once daily
Study NCT01288196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 6785 SC
Description: A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
Study NCT01288196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: A single SC dose of placebo administered in up to 3 SC injections
Study NCT04453449 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam given as a sedative during diagnostic lumbar medial branch block
Study NCT02363738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
Study NCT02158325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior capsulorhexis sizes
Description: Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)
Study NCT02158325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior capsulorhexis sizes
Description: Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)
Study NCT00739024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, oral, once daily
Study NCT04411459 — intervention group
Intervention type: OTHER
Intervention: Invasive mechanical ventilation
Description: Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
Study NCT01736410 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab, TS ONE, Cisplatin
Description: The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
Study NCT02361463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D vision
Description: Laparoscopic simulator training to proficiency under 3D conditions
Study NCT02361463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D vision
Description: Laparoscopic simulator training to proficiency under 2D conditions
Study NCT02980068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15N Nitrate
Description: 1,000 mg/11.8 mmol, oral, on day one, hour zero
Study NCT02980068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14N Nitrate
Description: 1,000 mg/11.18 mmol, oral, on day hour, hour zero
Study NCT03384030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted STMST
Description: Participants are subjected to the adapted STMST to induce emotional sweating.
Study NCT02678169 — intervention group
Intervention type: DEVICE
Intervention: Penumbra Aspiration System
Description: Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
Study NCT03809338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: amh test
Description: Antral follicle count with ultrasound on the 3rd day of menstruation
Study NCT03661619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
Description: Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
Study NCT03661619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
Description: Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
Study NCT03876743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1-Knee Arthroscopy
Description: Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
Study NCT03876743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2-Knee Arthroscopy
Description: Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
Study NCT03876743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1-ACL reconstruction
Description: Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
Study NCT03876743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2-ACL reconstruction
Description: Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
Study NCT02122887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peace-Building Intervention Process
Description: The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders.
Study NCT03369444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLT180a
Description: FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
Study NCT02333409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
Study NCT02333409 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
Study NCT01743365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-5FU-Afatinib
Study NCT02045628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investment intervention
Description: Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
Study NCT03581721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer
Description: The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group
Study NCT03351374 — intervention group
Intervention type: OTHER
Intervention: Software
Description: multi-module system of web software tools
Study NCT03595904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Motivate group
Description: Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
Study NCT03595904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
Study NCT01349075 — intervention group
Intervention type: RADIATION
Intervention: TheraSphere
Description: The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
Study NCT03558048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
Study NCT02423187 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT03193164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
Study NCT03193164 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation
Description: The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
Study NCT03193164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decubitus Position with the limbs raised to 20º
Description: The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
Study NCT03193164 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Decubitus Position with the limbs raised to 20º
Description: The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
Study NCT03157713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Directed Financial Incentives
Description: Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
Study NCT03157713 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
Study NCT03157713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
Study NCT03157713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outcome-based Financial Incentives
Description: Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to \<2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to \<5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to \<5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
Study NCT03790787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
Study NCT01993069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar-based Yoga Training
Description: 6 weekly Iyengar-based yoga classes
Study NCT03882476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InSight
Description: Clinical decision support (CDS) system for sepsis detection
Study NCT03790787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: Glucokinase activator currently under development
Study NCT01738581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
Study NCT01738581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Retraining
Description: For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
Study NCT00241254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (drug)
Description: IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
Study NCT00241254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (drug)
Description: Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
Study NCT03687086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program A
Description: Cognitive behavioral therapy type A plus medications prepared in packaging type A.